Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XDGNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KD.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCSNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.7.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.15.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CR.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KB.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CJ.1.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XANNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.4.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DV.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EU.1.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.43NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JB.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.28 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.272NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.353NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.407NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.160.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.182NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.218NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.12.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.22 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.128NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.405NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.296NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.412NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AC.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.421NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.364NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.82NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.61NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.251NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.55NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HH.8.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used